-
1
-
-
33846006173
-
The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
-
Drucker DJ, Nauck MA,. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006; 368 (9548): 1696-1705.
-
(2006)
Lancet
, vol.368
, Issue.9548
, pp. 1696-1705
-
-
Drucker, D.J.1
Nauck, M.A.2
-
2
-
-
0032005005
-
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans
-
Flint A, Raben A, Astrup A, Holst JJ,. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998; 101 (3): 515-520.
-
(1998)
J Clin Invest
, vol.101
, Issue.3
, pp. 515-520
-
-
Flint, A.1
Raben, A.2
Astrup, A.3
Holst, J.J.4
-
3
-
-
0033021677
-
Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men
-
Naslund E, Barkeling B, King N, et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord. 1999; 23 (3): 304-311.
-
(1999)
Int J Obes Relat Metab Disord
, vol.23
, Issue.3
, pp. 304-311
-
-
Naslund, E.1
Barkeling, B.2
King, N.3
-
4
-
-
0030068620
-
Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients
-
Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA,. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab. 1996; 81 (1): 327-332.
-
(1996)
J Clin Endocrinol Metab
, vol.81
, Issue.1
, pp. 327-332
-
-
Willms, B.1
Werner, J.2
Holst, J.J.3
Orskov, C.4
Creutzfeldt, W.5
Nauck, M.A.6
-
5
-
-
60549097258
-
Targeting incretins in Type 2 diabetes: Role of GLP-1 receptor agonists and DPP-4 inhibitors
-
Pratley RE, Gilbert M,. Targeting incretins in Type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors. Rev Diabet Stud. 2008; 5 (2): 73-94.
-
(2008)
Rev Diabet Stud
, vol.5
, Issue.2
, pp. 73-94
-
-
Pratley, R.E.1
Gilbert, M.2
-
6
-
-
80051503024
-
Novel incretin-based agents and practical regimens to meet needs and treatment goals of patients with type 2 diabetes mellitus
-
Garber AJ,. Novel incretin-based agents and practical regimens to meet needs and treatment goals of patients with type 2 diabetes mellitus. J Am Osteopath Assoc. 2011; 111 (7 Suppl 5): S20-S30.
-
(2011)
J Am Osteopath Assoc
, vol.111
, pp. S20-S30
-
-
Garber, A.J.1
-
7
-
-
79955013099
-
Incretin-based therapies - Review of the physiology, pharmacology and emerging clinical experience
-
Martin JH, Deacon CF, Gorrell MD, Prins JB,. Incretin-based therapies-review of the physiology, pharmacology and emerging clinical experience. Intern Med J. 2011; 41 (4): 299-307.
-
(2011)
Intern Med J
, vol.41
, Issue.4
, pp. 299-307
-
-
Martin, J.H.1
Deacon, C.F.2
Gorrell, M.D.3
Prins, J.B.4
-
8
-
-
79955930032
-
Incretin-based therapy: A powerful and promising weapon in the treatment of type 2 diabetes mellitus
-
Koliaki C, Doupis J,. Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus. Diabetes Ther. 2011; 2 (2): 101-121.
-
(2011)
Diabetes Ther
, vol.2
, Issue.2
, pp. 101-121
-
-
Koliaki, C.1
Doupis, J.2
-
9
-
-
67449096006
-
Potential of liraglutide in the treatment of patients with type 2 diabetes
-
Deacon CF,. Potential of liraglutide in the treatment of patients with type 2 diabetes. Vasc Health Risk Manag. 2009; 5 (1): 199-211.
-
(2009)
Vasc Health Risk Manag
, vol.5
, Issue.1
, pp. 199-211
-
-
Deacon, C.F.1
-
11
-
-
84887840117
-
Weight maintenance and additional weight loss with liraglutide after low-calorie diet-induced weight loss: The SCALE Maintenance randomized study
-
Wadden T, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013; 37 (11): 1443-1451.
-
(2013)
Int J Obes (Lond)
, vol.37
, Issue.11
, pp. 1443-1451
-
-
Wadden, T.1
Hollander, P.2
Klein, S.3
-
12
-
-
84874949437
-
The once-weekly human GLP-1 analogue semaglutide provides significant reductions in HbA1c and body weight in patients with type 2 diabetes
-
Nauck MA, Petrie JR, Sesti G,. The once-weekly human GLP-1 analogue semaglutide provides significant reductions in HbA1c and body weight in patients with type 2 diabetes. Diabetologia. 2012; 55 (Suppl 1): S7(2-OP).
-
(2012)
Diabetologia
, vol.55
, pp. S72-OP
-
-
Nauck, M.A.1
Petrie, J.R.2
Sesti, G.3
-
13
-
-
84903166001
-
The human GLP-1 analogs liraglutide and semaglutide: Absence of histopathological effects on the pancreas in nonhuman primates
-
Gotfredsen CF, Molck AM, Thorup I, et al. The human GLP-1 analogs liraglutide and semaglutide: Absence of histopathological effects on the pancreas in nonhuman primates. Diabetes. 2014; 63 (7): 2486-2497.
-
(2014)
Diabetes
, vol.63
, Issue.7
, pp. 2486-2497
-
-
Gotfredsen, C.F.1
Molck, A.M.2
Thorup, I.3
-
15
-
-
84894465077
-
Drug interactions and hormonal contraception
-
Rhoda Lee C,. Drug interactions and hormonal contraception. Trends Urol. Gynecol Sexual Health. 2009; 14 (3): 23-26.
-
(2009)
Trends Urol. Gynecol Sexual Health
, vol.14
, Issue.3
, pp. 23-26
-
-
Rhoda Lee, C.1
-
16
-
-
82955241439
-
Treatment with liraglutide - A once-daily GLP-1 analog - Does not reduce the bioavailability of ethinyl estradiol/levonorgestrel taken as an oral combination contraceptive drug
-
Jacobsen LV, Vouis J, Hindsberger C, Zdravkovic M,. Treatment with liraglutide-a once-daily GLP-1 analog-does not reduce the bioavailability of ethinyl estradiol/levonorgestrel taken as an oral combination contraceptive drug. J Clin Pharmacol. 2011; 51 (12): 1696-1703.
-
(2011)
J Clin Pharmacol
, vol.51
, Issue.12
, pp. 1696-1703
-
-
Jacobsen, L.V.1
Vouis, J.2
Hindsberger, C.3
Zdravkovic, M.4
-
17
-
-
84855680846
-
Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults
-
Tzefos M, Harris K, Brackett A,. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults. Ann Pharmacother. 2012; 46 (1): 68-78.
-
(2012)
Ann Pharmacother
, vol.46
, Issue.1
, pp. 68-78
-
-
Tzefos, M.1
Harris, K.2
Brackett, A.3
-
18
-
-
84858318559
-
Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: An open-label, randomised, crossover trial
-
Kothare PA, Seger ME, Northrup J, Mace K, Mitchell MI, Linnebjerg H,. Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial. BMC Clin Pharmacol. 2012; 12: 8.
-
(2012)
BMC Clin Pharmacol
, vol.12
, pp. 8
-
-
Kothare, P.A.1
Seger, M.E.2
Northrup, J.3
Mace, K.4
Mitchell, M.I.5
Linnebjerg, H.6
-
20
-
-
84926066152
-
-
World Medical Association. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. 52nd WMA General Assembly, Edinburgh, Scotland, October 2000. Last amended with Note of Clarification on Paragraph 29 by the WMA General Assembly, Washington 2002 Tokyo 2004
-
World Medical Association. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. 52nd WMA General Assembly, Edinburgh, Scotland, October 2000. Last amended with Note of Clarification on Paragraph 29 by the WMA General Assembly, Washington 2002; and Note of Clarification on Paragraph 30 by the WMA General assembly, Tokyo 2004. http://www.wma.net/en/30publications/10policies/b3/index.html.
-
Note of Clarification on Paragraph 30 by the WMA General Assembly
-
-
-
22
-
-
79955690629
-
-
European Medicines Agency (EMA) CPMP/EWP/560/95/Rev. 1 Corr, June 21
-
European Medicines Agency (EMA),. Guideline on the Investigation of Drug Interactions. CPMP/EWP/560/95/Rev. 1 Corr, June 21, 2012. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/07/WC500129606.pdf.
-
(2012)
Guideline on the Investigation of Drug Interactions
-
-
-
23
-
-
18144388647
-
American Diabetes Association. Defining and reporting hypoglycemia in diabetes: A report from the American Diabetes Association Workgroup on Hypoglycemia
-
American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005; 28 (5): 1245-1249.
-
(2005)
Diabetes Care
, vol.28
, Issue.5
, pp. 1245-1249
-
-
-
24
-
-
33646024613
-
Hy's law: Predicting serious hepatotoxicity
-
Temple R,. Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf. 2006; 15 (4): 241-243.
-
(2006)
Pharmacoepidemiol Drug Saf
, vol.15
, Issue.4
, pp. 241-243
-
-
Temple, R.1
-
25
-
-
84875798188
-
Effects of multiple doses of albiglutide on the pharmacokinetics, pharmacodynamics, and safety of digoxin, warfarin, or a low-dose oral contraceptive
-
Bush M, Scott R, Watanalumlerd P, Zhi H, Lewis E,. Effects of multiple doses of albiglutide on the pharmacokinetics, pharmacodynamics, and safety of digoxin, warfarin, or a low-dose oral contraceptive. Postgrad Med. 2012; 124 (6): 55-72.
-
(2012)
Postgrad Med
, vol.124
, Issue.6
, pp. 55-72
-
-
Bush, M.1
Scott, R.2
Watanalumlerd, P.3
Zhi, H.4
Lewis, E.5
-
26
-
-
70349093453
-
The effect of the once-daily human GLP-1 analogue liraglutide on the pharmacokinetics of paracetamol
-
Kapitza C, Flint A, Hindsberger C, Zdravkovic M,. The effect of the once-daily human GLP-1 analogue liraglutide on the pharmacokinetics of paracetamol. Diabetes Care. 2008; 57 (suppl 1): A593.
-
(2008)
Diabetes Care
, vol.57
, pp. A593
-
-
Kapitza, C.1
Flint, A.2
Hindsberger, C.3
Zdravkovic, M.4
-
27
-
-
39149113435
-
Novel ethinyl estradiol-beta-cyclodextrin clathrate formulation does not influence the relative bioavailability of ethinyl estradiol or coadministered drospirenone
-
Blode H, Schurmann R, Benda N,. Novel ethinyl estradiol-beta-cyclodextrin clathrate formulation does not influence the relative bioavailability of ethinyl estradiol or coadministered drospirenone. Contraception. 2008; 77 (3): 171-176.
-
(2008)
Contraception
, vol.77
, Issue.3
, pp. 171-176
-
-
Blode, H.1
Schurmann, R.2
Benda, N.3
-
28
-
-
84876975371
-
The once-weekly human GLP-1 analogue semaglutide provides significant reductions in HbA1c and body weight in patients with type 2 diabetes
-
Oral presentation 2 (Trial: NN9535-1821).
-
Nauck MA, Petrie JR, Sesti G, et al. The once-weekly human GLP-1 analogue semaglutide provides significant reductions in HbA1c and body weight in patients with type 2 diabetes. EASD. 2012. Oral presentation 2 (Trial: NN9535-1821).
-
(2012)
EASD
-
-
Nauck, M.A.1
Petrie, J.R.2
Sesti, G.3
-
29
-
-
84870054636
-
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
-
Meier JJ,. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012; 8 (12): 728-742.
-
(2012)
Nat Rev Endocrinol
, vol.8
, Issue.12
, pp. 728-742
-
-
Meier, J.J.1
-
30
-
-
84864674632
-
Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting
-
Lando HM, Alattar M, Dua AP,. Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting. Endocr Pract. 2012; 18 (4): 472-477.
-
(2012)
Endocr Pract
, vol.18
, Issue.4
, pp. 472-477
-
-
Lando, H.M.1
Alattar, M.2
Dua, A.P.3
|